Zoetis Inc.

Zoetis is a global animal health company that discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. Its products are used for companion animals such as dogs, cats, and horses, as well as livestock including cattle, swine, poultry, fish, and sheep. Key product categories include parasiticides, vaccines, dermatology treatments, anti-infectives, pain and sedation medications, and other pharmaceuticals. The company also offers point-of-care diagnostic products, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and non-pharmaceutical items like nutritional products. Zoetis markets its products to veterinarians, livestock producers, and pet owners globally.

Zoetis Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol ZTS. Its shares are traded in US Dollars (USD), as the company is headquartered in the United States. The exchange and currency reflect its primary listing in the US market, making it accessible to investors trading on US exchanges.

Zoetis operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification reflects its focus on developing and producing pharmaceutical products for animal health, including both branded and generic-like treatments. As a specialty drug manufacturer, Zoetis targets specific therapeutic areas in veterinary medicine, such as parasiticides, vaccines, and dermatology, rather than broad human healthcare.

Zoetis is headquartered in Parsippany, New Jersey, United States. The company was incorporated in 2012 and serves markets globally, including the United States and international regions. Its products are commercialized across companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). Zoetis markets its solutions to veterinarians, livestock producers, and pet owners worldwide, leveraging a broad geographic reach.

Zoetis generates revenue by selling a wide range of animal health products and services. Its portfolio includes pharmaceuticals (parasiticides, vaccines, dermatology, anti-infectives, pain and sedation), animal health diagnostics (point-of-care diagnostic products, instruments, reagents, rapid tests, reference lab kits, blood glucose monitors), and non-pharmaceutical items (nutritionals, biodevices, genetic tests, precision animal health solutions). The company also collaborates with partners like Blacksmith Medicines, Inc. to develop novel antibiotics for animal health. Revenue comes from sales to veterinarians, livestock producers, and pet owners across the US and globally.